FUROXONE
LOE ApproachingNDAORALSUSPENSION
Approved
Jan 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUROXONE is an oral suspension small molecule approved in 1958 by Takeda for undisclosed indications. The mechanism of action and specific therapeutic use are not documented in available data, limiting clinical context.
LOE Approaching
With LOE approaching and no linked job openings, this is a legacy asset in managed decline with minimal commercial team expansion expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FUROXONE represents a minimal career opportunity with zero linked job openings and approaching loss of exclusivity. Working on this product offers limited visibility and growth potential; roles are primarily defensive (supply management, compliance) rather than innovation-focused.
Brand ManagerSupply Chain Manager
Worked on FUROXONE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.